

BCOP Clinical Sessions



Welcome!

The BCOP Clinical Sessions are part of the professional development program for the recertification of board-certified oncology pharmacists, approved by the Board of Pharmacy Specialties and cosponsored by the American College of Clinical Pharmacy and the American Society of Health-System Pharmacists (ASHP).

Earning BCOP Recert Credit

To earn BCOP Recertification Credit for this session you must attend the session or view the full recording of the session (available at www.accp.com) and then successfully submit and pass the post-test for the session no later than **March 1, 2017.**

Access to the Recertification Posttest

- Participants who pre-paid the post-test fee for the BCOP Clinical Sessions will have access to the posttest immediately following the session at www.accp.com/myaccount.
- Participants who paid the posttest fee in Las Vegas will receive access no later than December 20.

BCOP Clinical Sessions Posttest Cont.

- Reminders:
 - Post-tests must be submitted by March 1, 2017
 - Participants may only submit the posttest one time.

BCOP Clinical Sessions: Multiple Myeloma and Pediatric CINV

**Jennifer Thackray, Pharm.D.,
BCPS, BCPPS**

Pediatric Oncology Clinical Pharmacy
Specialist
Memorial Sloan Kettering Cancer
Center
New York, New York

**Jill S. Bates, Pharm.D., M.S., BCOP,
CPP**

Clinical Pharmacist Practitioner, Myeloma
and Lymphoma
University of North Carolina Medical Center,
Chapel Hill, North Carolina



Disclosures

Jennifer Thackray:

- I will be discussing the off-label (non-FDA approved) use of medication in pediatric patients

Objectives

- Define the phases of chemotherapy-induced nausea and vomiting (CINV) and recognize the risk factors for CINV in a pediatric patient
- Analyze the safety and efficacy of aprepitant and palonosetron in pediatric patients
- Develop a plan for prevention and treatment of each phase of CINV
- Modify an antiemetic regimen for a pediatric patient with breakthrough CINV

Objectives

- Examine prognostic implications and outline patient-specific treatment for multiple myeloma
- Discuss pertinent literature related to ixazomib, elotuzumab and daratumumab
- Illustrate the current roles in therapy of novel agents to treat multiple myeloma

Management of Pediatric Chemotherapy-Induced Nausea and Vomiting: A Complex Case

Jennifer Thackray, Pharm.D., BCPS, BCPPS

Pediatric Oncology Clinical Pharmacy Specialist



Memorial Sloan Kettering Cancer Center

New York, New York



Time for a Poll

How to vote via the web or text messaging



How to vote via text message

How's my presentation so far?

Respond at PollEv.com/ashp Text a **KEYWORD** to 22333



How to vote via the web

How's my presentation so far?

Respond at PollEv.com/ashp Text a **KEYWORD** to 22333

It's amazing. **152964**

It's incredibly amazing! **152965**

It's aw-right. **152968**

0%



Question 1

What percentage of your pediatric patients experience breakthrough CINV that necessitates a change in therapy (PRN to scheduled, antiemetic switch, addition or escalation)?

- A** > 80%
- B** 50 – 79%
- C** 20 – 49%
- D** < 20%

Question 1

Your poll will show here

1

Install the app from
pollev.com/app

2

Make sure you are in
Slide Show mode

Still not working? Get help at pollev.com/app/help
or

[Open poll in your web browser](#)

Question 1


What percentage of your pediatric patients experience breakthrough CINV that necessitates a change in therapy (PRN to scheduled, antiemetic switch, addition or escalation)?

- A** > 80%
- B** 50 – 79%
- C** 20 – 49%
- D** < 20%


Introduction

- Highly emetogenic chemotherapy (HEC) is still associated with ~40% breakthrough CINV
- Higher rate in pediatrics than adults
 - Pathogenesis of CINV
 - Higher emetogenicity of chemotherapy regimens
 - Variability of PK parameters and metabolic profiles


Nausea Frequency (n=40)



Vomiting Frequency (n=40)



Risk Factors



Chemo-related factors

Emetogenicity of regimen
 Method of administration

Radiation-related factors

Dose and type regimen
 Administration schedule
 Fractionated or not
 Body location
 Area of radiation field


Surgery-related factors

Type and length of surgery
 Anesthetic regimen
 Premedication
 Gastric distention
 Movement post-surgery
 Post-op pain and analgesics
 Oral intake

Complications

- Physiologic
 - Malnutrition
 - Weight loss
 - Esophageal tears
 - Dehydration
 - Fatigue
- Psychological
 - Anxiety
 - Non-adherence
 - Reduced future chemotherapy doses
 - Decreased quality of life
- Metabolic
 - Electrolyte imbalances

Neurotransmitters



D₂: Dopamine 2 receptor
 5-HT₃: Serotonin type 3 receptor
 NK₁: Neurokinin 1 receptor (Substance P)

H₁: Histamine 1 receptor
 M: Muscarinic cholinergic receptor (Acetylcholine)

Current Standard of Care for Prevention of Pediatric CINV



Phases of CINV

5HT₃RA
 DEXA
 D₂RA
 OLZ

Acute

- < 24 hours after chemotherapy
- Correlates with administration of chemotherapy

Delayed

- > 24 hours following completion of chemotherapy
- Mechanism not fully understood
 - Substance P/NK₁ receptors

NK₁RA
 DEXA
 OLZ
 PALO?

BZD
 Music therapy
 Acupuncture
 Hypnosis

Anticipatory

- Learned reaction
- Cerebral cortex
- Many triggers (smell, sight, touch)

Breakthrough

- CINV during the acute or delayed phase despite antiemetic prophylaxis

H₁RA
 D₂RA
 OLZ
Patient specific

5-HT₃ RA, Serotonin receptor antagonist; DEXA, dexamethasone; D₂ RA, Dopamine 2 receptor antagonist; OLZ, olanzapine; BZD, benzodiazepine; NK₁ RA, Neurokinin 1 receptor antagonist; PALO, palonosetron; H₁ RA, Histamine 1 receptor antagonist

Refractory CINV

- Not well defined
- N/V during subsequent chemotherapy cycles when antiemetic prophylaxis has not been successful in previous cycles
- If multiple rescues or switches were made, consider upgrading CINV prophylaxis for next cycle

Standard of Care

High Risk (> 90%)

Carboplatin / Cisplatin
 Cyclophosphamide $\geq 1 \text{ g/m}^2$
 Cytarabine (Ara-C) 3 g/m^2
 Methotrexate (MTX) $\geq 12 \text{ g/m}^2$
 Thiotepa $\geq 300 \text{ mg/m}^2$

HEC $\geq 12 \text{ yr}$

HEC $< 12 \text{ yr}$

Aprepitant

Ondansetron
or Granisetron

DEXA

Ondansetron
or Granisetron

DEXA

Moderate (30-90%)

Clofarabine
 Ara-C $\leq 200 \text{ mg/m}^2$
 Dauno/Doxorubicin
 MTX $0.25\text{-}12 \text{ g/m}^2$
 Irinotecan

MEC

Ondansetron
or Granisetron

DEXA

Low (10-30%)

Etoposide
 MTX $51\text{-}250 \text{ mg/m}^2$
 Topotecan
 Busulfan (PO)

LEC

Ondansetron
or
Granisetron

Minimal (< 10%)

Asparaginase
 Mercaptopurine
 Vincristine
 Vinorelbine

Minimal

No routine
prophylaxis

HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; LEC, low emetogenic chemotherapy

Dupuis LL, et al. *Pediatr Blood Cancer*. 2011;57:191-8. Dupuis LL, et al. *Pediatr Blood Cancer*. 2013;60:1073-1082.

Basch E, et al. *J Clin Oncol*. 2011;29:4189-98.

Serotonin Receptor Antagonists (5HT₃RAs)

5-HT₃ Receptor Antagonists

- Cornerstone of acute CINV prophylaxis
- Blocks serotonin peripherally (vagal nerve terminals) and centrally (CTZ)
- Threshold effect for response and modest dose-response curve above specific dose

Ondansetron: 1st Generation 5-HT₃RA

- First in class
- 2012 FDA label change
 - Peak concentration associated with increased risk of Torsades de Pointes
- Pediatrics: 0.15 mg/kg (max 16 mg) IV Q4H x 3 doses
- IVCI = single dose = multiple daily doses

Granisetron: 1st Generation 5-HT₃RA

- FDA-labeled dosing
 - 2 – 17 yr: 10 mcg/kg IV
 - Adults: 10 mcg/kg IV; 2 mg PO daily or divided BID

Miyajima, et al

- Prospective, crossover
 - GRAN vs. conventional antiemetics
 - GRAN 40 mcg/kg IV 30 min prior to HEC
 - Acute CINV CR = 60% (vs. 0%, p<0.001)

Komada, et al

- Randomized trial (N=49; Mean age 6.3 yr)
- GRAN 20 vs. GRAN 40 (HEC)
- Acute CINV CR > 80% in both groups
- Similar safety profile

- 2013 POGO Consensus Acute CINV
 - 40 mcg/kg IV (no max) as a single daily dose prior to HEC/MEC
 - 40 mcg/kg PO BID

Palonosetron: 2nd Generation 5-HT₃RA

- Peripherally and centrally acting
- Longer duration of action and higher affinity
 - Biologic duration of action = 120 hr (adults)
 - Half-life elimination ~20-30 hr (peds); ~40 hr (adults)
 - Onset of action = 2 hr (adults)
- Toxicity
 - Similar rates of constipation and headache in adults
 - Lower risk of QTc prolongation than first generation 5-HT₃RAs
- Dosing
 - 1 mon to 16 yr: 20 mcg/kg (max 1.5 mg) IV beginning ~30 min prior to chemotherapy
 - ≥ 17 yr: 0.25 mg IV beginning ~30 min prior to chemotherapy

Palonosetron in Pediatrics

- Phase III, randomized, double-blind, double-dummy, non-inferiority trial
 - 1° endpoint: Non-inferiority of PALO vs. OND for acute CINV ($\delta = -15\%$)
 - 2° endpoints: CR in delayed and overall CINV
 - 493 pediatric patients receiving up to 4 MEC/HEC cycles

- Intervention: Day 1 of chemotherapy
 - PALO 10 mcg/kg IV (n = 166)
 - PALO 20 mcg/kg IV (n = 165)
 - OND 0.15 mg/kg IV Q4H x 3 (n = 162)

Palonosetron in Pediatrics

- Patient characteristics (N = 493)
 - Mean age 8 yr (range 2.5 mon – 16.92 yr)
 - 50% male; 85% white
 - 25% leukemia/lymphoma
 - 25% naïve to chemotherapy
 - 33% HEC; 67% MEC
 - 52% Day 1 chemo only
 - 48% multi-day chemo (up to 6 days)
 - 32% received dexamethasone at some point on days 1 – 6
 - 55% received concomitant corticosteroids
 - Allowed prophylactic antiemetics for chemotherapy after day 1 according to standard of practice

Palonosetron Efficacy & Safety

First On-Study Cycle	PALO 10 mcg/kg IV (n = 166)	PALO 20 mcg/kg IV (n = 165)	OND 0.15 mg/kg IV Q4H x3 (n = 162)
Acute (Day 1) CR _{0-24h} , 97.5% CI	54% (-16.4 – 7.6); p = 0.0242	59% (-11.7 – 12.4); p = 0.0022	59% -
Delayed (Days 2-5) CR _{25-120h} , 97.5% CI	29% (-9.4 – 10.3)	39% (-0.1 – 20.4)	28% -
Overall (Days 1-5) CR _{0-120h} , 97.5% CI	23% (-10 – 8.8)	33% (-16.4 – 7.6)	24% -

- Treatment-emergent adverse events were similar in all three groups (4%)
 - Headache (2%), cardiac (< 1%)

Palonosetron 20 mcg/kg (max 1.5 mg) IV 30 minutes prior to HEC or MEC is *non-inferior* to ondansetron for **acute, delayed and overall** CINV in 1 mon to 17 years

PALO: What We Know From Adults

Highly Emetogenic Chemotherapy (HEC)		
	Acute	Delayed
(+) DEX	PALO = GRAN (~70%) PALO = OND (~60%)	PALO (57%) > GRAN (45%) PALO (41%) > OND (25%)
(-) DEX	PALO = GRAN (~68%)	PALO = GRAN (68%)

Moderately Emetogenic Chemotherapy (MEC)		
	Acute	Delayed
(+) DEX	-	-
(-) DEX	PALO (81%) > OND (69%)	PALO (74%) > OND (55%)

Palonosetron: Summary

- Kovacs, et al 2016 (Pediatrics)
 - In acute CIV, PALO_±DEX is non-inferior to OND_±DEX for control of acute, delayed HEC or MEC
- Popovic, et al 2014 (Adults and Pediatrics)
 - In acute CIV, PALO is comparable to other 5HT₃RAs with DEX (OR 1.14; 95% CI 0.88-1.49)
 - For delayed CINV, PALO is superior to other 5HT₃RAs with or without DEX
 - DEX: OR 1.65; 95% CI 1.31-2.08
 - No DEX: OR 1.57; 95% CI 1.18-2.1

Question 2

RH is a 4 year-old (18 kg, 110 cm, 0.74 m²) female with osteosarcoma here for cycle 4 of cisplatin and doxorubicin. The antiemetics ordered are palonosetron 0.35 mg IV and dexamethasone 6 mg IV to be given 30-60 minutes prior to chemotherapy. Which of the following is true regarding palonosetron dosing?

- A** Underdosed
- B** Overdosed
- C** Correctly dosed
- D** Palonosetron is not safe to be used in pediatrics

Question 2



Your poll will show here

1

Install the app from
pollev.com/app

2

Make sure you are in
Slide Show mode

Still not working? Get help at pollev.com/app/help
or

[Open poll in your web browser](#)



Question 2

RH is a 4 year-old (18 kg, 110 cm, 0.74 m²) female with osteosarcoma here for cycle 4 of cisplatin and doxorubicin. The antiemetics ordered are palonosetron 0.35 mg IV and dexamethasone 6 mg IV to be given 30-60 minutes prior to chemotherapy. Which of the following is true regarding palonosetron dosing?

- A Underdosed
- B Overdosed
- C Correctly dosed**
- D Palonosetron is not safe to be used in pediatrics

5HT₃RA of Choice - Pediatrics

Ondansetron

- Most experience
- Highest risk of QTc prolongation?
- Multiple dosing formulations
- Multiple dosing schedules

Granisetron

- Weak literature to support pediatric dosing
- Similar safety and efficacy to ondansetron

Palonosetron

- FDA-approval for 1 month and older
- Delayed CINV benefit?
- Lowest rate of side effects
- IV only
- Re-dosing information lacking


- Comparative efficacy appears to be affected by the presence of dexamethasone
- Higher doses required for efficacy in pediatric patients
- Similar safety profiles to adult patients, despite higher doses

NK₁ Receptor Antagonist

NK₁ Receptor Antagonist

- Blocks substance P from activating the neurokinin-1 (NK₁) receptors in the CNS
- Augments effects of 5HT₃RAs and dexamethasone
- Potentially significant drug-drug interactions
 - CYP3A4 substrate, inhibitor & inducer
 - CYP2C9 inducer
- Aprepitant recently studied in pediatric patients

The Aprepitant Story



Aprepitant in Pediatrics

- Phase 3, multi-center, double-blind, randomized trial
 - 1° endpoint: CR during delayed phase (CR_{25-120h}) after Day 1 chemotherapy

- Intervention
 - APREP (Days 1-3) + OND (mean duration 3 days)
 - 6 mon – 12 yr: 3 mg/kg PO Day 1, 2 mg/kg Day 2, 3 (powder for suspension)
 - 12 – 17 yr: 125 mg PO Day 1, 80 mg Day 2, 3 (capsules)
 - OND alone (mean duration 2.8 days)
 - Dose according to site (mean 0.18 mg/kg)

Aprepitant in Pediatrics

- Patient characteristics (N = 302)
 - Mean age 7 yr (range 0.5 – 17.8 yr)
 - 55% male; 75% white
 - 40% naïve to chemotherapy
 - 66% HEC; 33% MEC
 - 85% received more than 1 day
 - Most patients received chemo for 3 days (range 1 – 7 days)
 - 28% received dexamethasone (0.05 – 0.44 mg/kg)

Aprepitant in Pediatrics

	APREP/OND ± DEX (n = 152)	OND ± DEX (n = 150)	P-value
Delayed (CR_{25-120h}) – ALL	<u>51%</u>	<u>26%</u>	<u>< 0.0001</u>
HEC	42%	20%	--
No HEC	66%	39%	--
Acute (CR_{0-24h}) – ALL	<u>66%</u>	<u>52%</u>	<u>0.0135</u>
HEC	65%	51%	--
No HEC	70%	55%	--
Overall (CR_{0-120h}) – ALL	<u>40%</u>	<u>20%</u>	<u>0.0002</u>
HEC	35%	14%	--
No HEC	49%	33%	--

“HEC” is represented in the trial as ‘VHEC’ and is defined as >90% emetogenic potential

“No HEC” is represented in the trial as ‘No VHEC’ and includes MEC and LEC

Question 3

BT is a 8 year-old (30 kg) male with metastatic osteosarcoma receiving his first cycle of chemotherapy with cisplatin and doxorubicin. Which of the following would be the best regimen for prevention of CINV?

- A** APREP + OND + DEX
- B** APREP + OND
- C** OND + DEX
- D** OND only

Question 3

Your poll will show here

1

Install the app from
pollev.com/app

2

Make sure you are in
Slide Show mode

Still not working? Get help at pollev.com/app/help
or

[Open poll in your web browser](#)

Question 3

BT is a 8 year-old (30 kg) male with metastatic osteosarcoma receiving his first cycle of chemotherapy with cisplatin and doxorubicin. Which of the following would be the best regimen for prevention of CINV?

- A APREP + OND + DEX**
- B APREP + OND**
- C OND + DEX**
- D OND only**

Aprepitant: Summary

- Kang, et al 2015 (Pediatrics)
 - APREP + OND ± DEX is safe and effective for acute and delayed CINV in patients 6 months and older receiving HEC
 - Efficacy in MEC not delineated
 - Role of dexamethasone undefined
- Capsule: 125 mg, 80mg (≥12 yr or ≥30kg)
- Oral solution
 - Commercial formulation (Oct 2016): 25 mg/mL with 72-hr stability
 - Published extemporaneous compound 20 mg/mL with 90-day stability

Future Standard of Care for Prevention of Pediatric CINV



Current Standard of Care

High Risk (> 90%)

Carboplatin / Cisplatin
 Cyclophosphamide $\geq 1 \text{ g/m}^2$
 Cytarabine (Ara-C) 3 g/m^2
 Methotrexate (MTX) $\geq 12 \text{ g/m}^2$
 Thiotepea $\geq 300 \text{ mg/m}^2$

HEC $\geq 12 \text{ yr}$

HEC < 12 yr

Aprepitant

Ondansetron
or Granisetron

DEXA

Ondansetron
or Granisetron

DEXA

Moderate (30-90%)

Clofarabine
 Ara-C $\leq 200 \text{ mg/m}^2$
 Dauno/Doxorubicin
 MTX $0.25\text{-}12 \text{ g/m}^2$
 Irinotecan

MEC

Ondansetron
or Granisetron

DEXA

Low (10-30%)

Etoposide
 MTX $51\text{-}250 \text{ mg/m}^2$
 Topotecan
 Busulfan (PO)

LEC

Ondansetron
or
Granisetron

Minimal (< 10%)

Asparaginase
 Mercaptopurine
 Vincristine
 Vinorelbine

Minimal

No routine
prophylaxis

HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; LEC, low emetogenic chemotherapy

New Standard of Care

High Risk
(> 90%)

Moderate
(30-90%)

Low
(10-30%)

Minimal
(< 10%)

HEC > 6 mon

MEC

LEC

Minimal

Aprepitant

Aprepitant?

Ondansetron or
Granisetron or
Palonosetron

Ondansetron or
Granisetron or
Palonosetron

Ondansetron or
Granisetron or
Palonosetron

No routine
prophylaxis

DEXA

DEXA

HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; LEC, low emetogenic chemotherapy

Treatment of Breakthrough CINV

Breakthrough CINV

1. PRN

- Choose drug from a different drug class to give as needed
- May require multiple agents

Diphenhydramine
Dronabinol
Haloperidol
Hydroxyzine
Lorazepam
Metoclopramide
Olanzapine
Promethazine
Scopolamine patch

2. Add

- Add 'as needed' drug to around the clock
- Choose drug from a different drug class to give around the clock

Ondansetron IVCI
Granisetron
Palonosetron

3. Switch

- Rotate drugs within same class
- Rotate schedule of medication
- Route has not been shown to be superior

Breakthrough CINV

Common Agents

Diphenhydramine	Metoclopramide
Dronabinol	Prochlorperazine
Hydroxyzine	Scopolamine
Lorazepam	

Newer or Controversial Agents

Aprepitant	Olanzapine
Dexamethasone	Palonosetron
Fosaprepitant	
Haloperidol	

Did the breakthrough medication control the patient's nausea and vomiting?

YES



Continue breakthrough medication scheduled (not PRN)

NO



Add (schedule) a drug from a different drug class *and* another PRN medication

Note patient-specific changes for next chemotherapy cycle!

Patient Case 1

- AJ is a 4 year-old girl (20 kg) with high-risk neuroblastoma who is post-op day (POD) 5 from primary tumor resection and starting cycle 4 chemotherapy today:
 - Cyclophosphamide 70 mg/kg IVPB over 6 hr x 2 days
 - Doxorubicin 25 mg/m² IVCI x 72 hr
 - Vincristine 0.022 mg/kg IVCI x 72 hr
- Prophylactic agents
 - Ondansetron IV continuous infusion
 - Dexamethasone IV daily
 - Lorazepam IV Q6H around the clock
- Breakthrough CINV agents
 - Metoclopramide IV Q6H PRN breakthrough nausea
 - Hydroxyzine PO Q6H PRN breakthrough nausea

On Day 3, AJ has vomited 3 times per day and has been persistently nauseated. Per mom, after receiving hydroxyzine the nausea subsides for “a little bit”

EMR documentation:
Metoclopramide IV x 3 per day
Hydroxyzine PO x 3 per day

Question 4

Which of the following changes should be made to control AJ's CINV?

- A** Add PO aprepitant
- B** Change PO hydroxyzine from PRN to scheduled
- C** Change IV ondansetron to IV granisetron
- D** Change IV metoclopramide to PO olanzapine

Question 4

Your poll will show here

1

Install the app from
pollev.com/app

2

Make sure you are in
Slide Show mode

Still not working? Get help at pollev.com/app/help
or

[Open poll in your web browser](#)

Question 4

Which of the following changes should be made to control AJ's CINV?

- A** Add PO aprepitant
- B** Change PO hydroxyzine from PRN to scheduled
- C** Change IV ondansetron to IV granisetron
- D** Change IV metoclopramide to PO olanzapine

Breakthrough CINV

1. PRN

- Choose drug from a different drug class to give as needed
- May require multiple agents

Diphenhydramine
Dronabinol
Haloperidol
Hydroxyzine
Lorazepam
Metoclopramide
Olanzapine
Promethazine
Scopolamine patch

2. Add


- Add 'as needed' drug to around the clock
- Choose drug from a different drug class to give around the clock

3. Switch

- Rotate drugs within same class
- Rotate schedule of medication
- Route has not been shown to be superior

Ondansetron IVCI
Granisetron
Palonosetron

Decisions, Decisions



Patient Case 2

- An 12 year-old female (40 kg) with Ewing sarcoma presents to clinic for cycle 2 chemotherapy
 - Ifosfamide 2800 mg/m² IVPB over 4 hr x 5 days
 - Etoposide 100 mg/m² IVPB over 1 hr x 5 days
- Antiemetic prophylaxis
 - Aprepitant 125 mg PO Day 1, 80 mg PO Day 2, 3
 - Ondansetron IV
 - Dexamethasone IV
 - Hydroxyzine PO PRN – not taking
 - Metoclopramide IV PRN – not taking overnight
- On Day 3, admitted for dehydration and electrolyte imbalances due to CINV
 - Metoclopramide IV Q6H

Additional Options:

~~Dronabinol (PO only)~~

Diphenhydramine – anticholinergic?

Famotidine – GERD?

~~Fosaprepitant (duplicate)~~

~~Granisetron (duplicate)~~

~~Haloperidol (adverse effect; EPS)~~

Hydroxyzine (PO only)

Lorazepam – Anxiety?

~~Olanzapine (PO only)~~

~~Palonosetron (duplicate)~~

~~Prochlorperazine (adverse effect; EPS)~~

Promethazine (PO only)

Scopolamine (age ≥ 13 yr)

Olanzapine (OLZ)

- Multiple-receptor antagonistic activity in CNS
 - 5-HT_{2A}, 5-HT_{2C}, D₁₋₄, H₁ and α_1 -adrenergic
- Compelling indications
 - Mood elevation, insomnia, anxiety, weight gain
- Clinical considerations
 - EPS risk
 - Serotonin syndrome
 - LFT elevation
 - No IV formulation

OLZ: What We Know From Adults

- OLZ vs. METO

- BT-CINV in HEC despite FOSAPREP + PALO + DEX

- OLZ 10 mg PO daily or METO 10mg PO TID (x 3 days)

- CR (no vomiting) in 72 hr period

- OLZ 70% (39/56) vs. METO 31% (16/52) $p < 0.01$

- OLZ + PALO + DEX vs. APREP + PALO + DEX

- Acute CR: 80% (97/121) vs. 73% (87/120); $p > 0.05$

- Delayed CR: 64% (77/121) vs. 61% (73/120); $p > 0.05$

OLZ: What We Know From Adults

- NK₁RA + 5HT₃RA + DEX ± OLZ (n=380)
 - 18 years and older receiving HEC
 - Acute CR higher in OLZ group
 - 86% (156/182) vs. 65% (117/181); p>0.001
 - Delayed CR higher in OLZ group
 - OLZ: 67% (109/163) vs. 52% (88/168); p>0.007

Olanzapine for CINV (Adults)

- NCCN Guidelines Version 2.2016
 - HEC/MEC Acute and Delayed Prevention option
 - NK₁RA + 5HT₃RA + DEX
 - OLZ 10 mg PO daily + PALO + DEX
 - Breakthrough CINV options
 - Add OLZ 10 mg PO daily (over metoclopramide)
 - Consider changing from NK₁-containing regimens to OLZ-containing regimen, or vice versa

OLZ for CINV (Pediatrics)

- 20 month, multi-center, retrospective review
- N=60; 159 cycles
 - Median age 13.2 yr (3.1 – 17.96 yr)
 - 50% sarcoma; 20% neuroblastoma; 12% CNS tumors; 10% ALL
 - Mean dose 0.1 ± 0.05 mg/kg/day
 - ADR: 7% sedation, 20% increased LFTs
 - \uparrow dose = \uparrow sedation (p=0.0001)
- OLZ started on Day 1 (83% HEC; 128 cycles)
 - 65% acute CIV control

Pros of Breakthrough CINV Agents

Agent	Compelling Indication									Notes
	Acid reflux	Anxiety	Appetite	Constipation	Depressed Mood	Diarrhea	Headache	Insomnia	Travel Sickness	
Diphenhydramine								Yes	Yes	Over the counter
Dronabinol			Yes		Yes					
Famotidine	Yes									Over the counter
Haloperidol		Yes						Yes		
Hydroxyzine								Yes	Yes	
Lorazepam		Yes						Yes		
Metoclopramide				Yes		No	Yes			
Olanzapine		Yes	Yes		Yes			Yes		Oral disintegrating tablet
Palonosetron				No		Yes				Long acting
Promethazine								Yes	Yes	
Scopolamine				No		Yes			Yes	Transdermal patch Q72H

Cons of Breakthrough CINV Agents

Agent	Contraindications/Precautions									
	Oral	IV	↓ CNS	↓ WBC	Age/Wt limit	QTc prolonging	EPS risk	Paradoxical effect	Anti-cholinergic	Notes
Aprepitant	Yes	No			≥ 12 yr or ≥ 30 kg					Insurance coverage; Drug interactions (CYP3A4)
Diphenhydramine	Yes	Yes						Yes	Yes	
Dronabinol	Yes	No	Yes							May ↓ seizure threshold; May worsen psych disorders; Contains sesame oil
Famotidine	Yes	Yes		Yes		Yes				GERD
Haloperidol	Yes	Yes	Yes	Yes	≥ 3 yr	Yes	Yes			
Hydroxyzine	Yes	No						Yes	Yes	
Lorazepam	Yes	Yes	Yes					Yes		Anxiolytic; Risk of dependence
Metoclopramide	Yes	Yes					Yes			↑ GI motility
Olanzapine	Yes	No	Yes	Yes			Yes			Drug interactions (5HT ₃); ↑LFTs
Palonosetron	No	Yes			≥ 1 mon					Constipation; Headache
Promethazine	Yes	Yes		Yes	≥ 2 yr	Yes		Yes		< 2 yr respiratory depression (BBW)
Scopolamine	No	No			≥ 13 yr				Yes	Patch contains aluminum (MRI)

Breakthrough CINV

1. PRN

- Choose drug from a different drug class to give as needed
- May require multiple agents

Diphenhydramine
Dronabinol
Haloperidol
Hydroxyzine
Lorazepam
Metoclopramide
Olanzapine
Promethazine
Scopolamine patch

2. Add

- Add 'as needed' drug to around the clock
- Choose drug from a different drug class to give around the clock

3. Switch

- Rotate drugs within same class
- Rotate schedule of medication
- Route has not been shown to be superior

Ondansetron IVCI
Granisetron
Palonosetron

Treatment of Breakthrough CINV

- Patient-specific interventions
- Implement changes for next cycle
 - Communication is key
- Better prevention
 - Focused update regarding optimal aprepitant and palonosetron use in pediatrics
 - To be published Fall 2016

Tips for Evaluating CINV Literature

- Emetogenic classification
 - Rate of control
- Moderate 30 – 90%: Broad range!
- Nausea or vomiting or both
- Type of CINV
- Concomitant steroid use

Barriers to Implementation

- Drug
 - Formulations (liquid not available, IV only)
 - Ages studied (restrictions, labeling)
 - Weak dosing recommendations for pediatrics in older medications
- Hospital
 - Formulary restrictions
- Cost
 - Insurance reimbursement

Looking Forward

- How clinically significant are the drug-drug interactions with aprepitant and chemotherapy?
- Is aprepitant effective and/or necessary for patients receiving MEC?
- Is palonosetron superior to for acute and/or delayed CINV in pediatrics?
- How often can palonosetron be re-dosed?
- Is fosaprepitant safe and effective in pediatrics?

Summary

- The high incidence of breakthrough CINV in pediatrics may decrease in the future as more aggressive CINV medications are studied (aprepitant, palonosetron)
- The 5-HT₃RAs are the cornerstone to preventing CINV, however the optimal 5-HT₃RA for pediatric patients is yet to be determined
- Pharmacists can play a big role in drug therapy management of CINV by recognizing compelling indications, adverse effects of various antiemetics and making interventions or upgrading prophylaxis for the next cycle

Evolving Treatment Strategies for Multiple Myeloma

Jill S. Bates, Pharm.D., M.S., BCOP, CPP

Clinical Pharmacist Practitioner, Myeloma and Lymphoma

**University of North Carolina Medical Center,
Chapel Hill, NC**



Patient Case

KH is a 46 year old female who presented with lower back pain that came on suddenly after lifting furniture. After several weeks of managing pain at home, KH came in for evaluation where a lumbar magnetic resonance image noted diffuse bony metastasis and compression fractures. Biopsy was obtained, labs as follows:

10
5.1 243
31.1

Mean Corpuscular Volume 99
Calcium 10.5

Patient case

Expedited workup of KH ensued. The following data was obtained:

Serum protein electrophoresis (SPEP) with immunofixation: monoclonal kappa free light chains (FLC), IgA kappa. Kappa FLC 637.5 mg/dL.

Bone marrow biopsy: hypercellular marrow with 80% involvement by plasma cell neoplasm. Monotypic kappa, CD138+.

FISH: FGFR3 deletion.

Routine cytogenetics: 46, XY.

Beta-2 microglobulin 3.07, albumin 4.5, Lactate dehydrogenase (LDH) 522

Question 5

Which of the following best describes KH's diagnosis?

- A** ISS 1 IgA kappa symptomatic multiple myeloma
- B** AL-amyloidosis
- C** ISS 2 IgG lambda asymptomatic multiple myeloma
- D** plasma cell leukemia

ISS= International Staging System
AL= amyloid light chain

Question 5

Your poll will show here

1

Install the app from
pollev.com/app

2

Make sure you are in
Slide Show mode

Still not working? Get help at pollev.com/app/help
or

[Open poll in your web browser](#)


Multiple Myeloma (MM)

- Estimated new cases of MM in 2016 are 30,330 with 12,650 estimated deaths
- Myeloma carries with it a 6.5% incidence rate (2009-2013), 3.3% mortality rate (2009-2013) and 48.5% survival rate (2006-2012)
- More prevalent in black ethnicity, males, and demonstrates clustering in families
- Median age of onset is 72 years

Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.


The Double Hit Hypothesis in MM

N
o
r
m
a
l




HIT #1

M
G
U
S



HIT #1


M
Y
E
L
O
M
A



Hallek, et al. Blood 1998;91:3-21.

Kuehl WM, et al. Nature Rev Cancer. 2002;2:175-87.


Spectrum of Disease Progression



Hallek, et al. Blood 1998;91:3-21.

Kuehl WM, et al. Nature Rev Cancer. 2002;2:175-87.


Monoclonality




Three Definitions of “Multiple Myeloma”

Disease process	Diagnostic criteria
Symptomatic multiple myeloma	Monoclonal plasma cells in the bone marrow ($\geq 10\%$) Plasmacytoma Presence of monoclonal protein in serum or urine Myeloma-related end organ damage (e.g. CRAB)
Smoldering or indolent myeloma	Monoclonal protein in serum $\geq 3\text{g}/100\text{ml}$ Monoclonal plasma cells in bone marrow $\geq 10\%$ or present in a tissue biopsy No evidence of end organ damage related to clonal plasma cells
MGUS	Serum monoclonal protein $< 3\text{g}/100\text{ml}$ Monoclonal plasma cells in the bone marrow $< 10\%$ No evidence of end organ damage related to clonal plasma cells


Myeloma-related Organ or Tissue Impairment



Laboratory Evaluation

Test	Type of Data
<p>Electrophoresis</p> 	<p>Method of separating proteins based on their physical properties. Can be used to identify a band of restricted mobility or M-spike.</p>
<p>Quantitative immunoglobulins</p>	<p>Measures the quantity of different immunoglobulins using either nephelometry or turbidimetry.</p>
<p>Immunofixation</p>	<p>Determines the type of immunoglobulin heavy chain and light chain once a band of restricted mobility is identified.</p>
<p>Free light chains</p>	<p>Measures the amount of free light chains in serum. SPEP only measures level of intact immunoglobulin in the blood.</p>
<p>Fluorescence in situ hybridization (FISH)</p>	<p>Use of genetically engineered probes to detect specific deoxyribonucleic acid (DNA) sequences.</p>

Laboratory Evaluation

Test	Type of Data
Electrophoresis 	Method of separating proteins based on their physical properties. Can be used to identify a band of restricted mobility or M-spike.
Quantitative immunoglobulins	Measures the quantity of different immunoglobulins using either nephelometry or turbidimetry.
Immunofixation	Determines the type of immunoglobulin heavy chain and light chain once a band of restricted mobility is identified.
Free light chains	Measures the amount of free light chains in serum. SPEP only measures level of intact immunoglobulin in the blood.
Fluorescence in situ hybridization (FISH)	Use of genetically engineered probes to detect specific deoxyribonucleic acid (DNA) sequences.

mSMART

High Risk	Intermediate Risk	Standard Risk
<ul style="list-style-type: none"> • Del 17p • t(14;16) [CMAF] • t(14;20) [MAFB] • Genomic Expression Profile (GEP) <ul style="list-style-type: none"> • High risk signature 	<ul style="list-style-type: none"> • t(4;14) [FGFR3/MMSET] • 1q gain • High PC S-phase 	<ul style="list-style-type: none"> • Trisomies • t(11;14) [CCND1] • t(6;14) [CCND3]

Revised International Staging System

	Criteria
rISS 1	β -microglobulin < 3.5 mg/dL, serum albumin \geq 3.5 g/dL, LDH < ULN, no high risk cytogenetic abnormalities
rISS 2	Not rISS stage 1 or 3
rISS 3	β -microglobulin \geq 5.5 mg/dL, LDH > ULN – or – presence of del(17p), and/or t(4;14), and/or t(14;16)

ULN= upper limit of normal

Response Criteria

Response	Criteria
sCR (stringent complete response)	In addition to CR criteria, normal FLC ratio and disappearance of plasma cell clones in the bone marrow by immunohistochemistry or fluorescence
CR (complete response)	Negative M-protein by immunofixation, disappearance of any plasmacytoma and < 5% plasma cells in the bone marrow
VGPR (very good partial response)	Serum and urine M-protein detectable by immunofixation but not electrophoresis
PR (partial response)	≥ 50% reduction in serum M-protein; ≥ 90% reduction in urine M-protein; ≥ 50% reduction in FLC ratio in those without M-protein; in addition if plasmacytoma present ≥ 50% reduction in size
PD (progressive disease)	Increase ≥ 25% in serum or urine M-protein; increased FLC ratio in those without detectable M-protein; ≥ 10% plasma cells in the bone marrow; new or worsening bone lesions or plasmacytoma; hypercalcemia attributed to myeloma
Relapse	Direct indicator of increasing disease or end organ involvement

Question 6

KH is diagnosed with ISS 1, IgA kappa symptomatic multiple myeloma. She is 46 years old with end organ involvement including bone lesions and anemia. Scr 0.98, total bilirubin 0.9, calcium 10.5. Which of the following is the best initial treatment for KH?

- A** elotuzumab, lenalidomide and dexamethasone
- B** lenalidomide, bortezomib and dexamethasone (RVD)
- C** bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, etoposide (VDT-PACE)
- D** daratumumab monotherapy plus zoledronic acid

Question 6

Your poll will show here

1

Install the app from
pollev.com/app

2


Make sure you are in
Slide Show mode

Still not working? Get help at pollev.com/app/help

or

[Open poll in your web browser](#)

Active Therapies in Multiple Myeloma



Initial Treatment of Newly Diagnosed Multiple Myeloma

- Historically, treatment for myeloma consisted of melphalan plus prednisone (MP)
- Aggressive combination chemotherapy did not demonstrate differences in two year survival compared with MP
 - MP: 57.5% (two year survival), 45.7 (median survival, months)
 - Combination chemotherapy: 55.5% (two year survival), 50.7 (median survival, months)
- High dose dexamethasone, autologous transplantation, and the introduction of novel agents improved outcomes in myeloma patients
- Triplet combinations demonstrate better efficacy than doublet combinations but with added toxicity

Preferred Induction Regimens for Newly Diagnosed MM: Patients eligible for transplant

Study*	Treatment	ORR	PFS
Harousseau JL, et al.	Bortezomib + Dexamethasone	78.5%	36 months
Sonneveld P, et al.	Bortezomib + Doxorubicin + Dexamethasone	78%	35 months
Cavo M, et al. Rosinol L, et al.	Bortezomib + Thalidomide + Dexamethasone	93.2% 85%	68% at 3 years 56.2 months
Zonder JA, et al. Gay F, et al.	Lenalidomide + Dexamethasone	Halted 80.3%	Halted 27.4 months
Richardson PG, et al. Roussel M, et al. Kumar S, et al.	Bortezomib + Lenalidomide + Dexamethasone	100% 93.5% 85%	75% at 18months 77% at 3 years 83% at 1 year
Reeder, et al. Kumar S, et al.	Cyclophosphamide + Bortezomib + Dexamethasone	88% 75%	42% at 5 years 93% at 1 year

ORR overall response rate, PFS progression free survival

*For full bibliographic citations see last slide

Preferred Induction Regimens for Newly Diagnosed MM: Patients ineligible for transplant

Study*	Treatment	ORR	PFS
Palumbo A, et al. Facon T, et al. Hulin C, et al. Wijermans P, et al.	Melphalan + prednisone + thalidomide	76% 76% 62% 66%	21.8 months 27.5 months 24.1 months 34% at 2 years
Palumbo A, et al.	Melphalan + prednisone + lenalidomide followed by lenalidomide maintenance	77%	31 months
San Miguel JF, et al.	Melphalan + prednisone + bortezomib	71%	19.9 months (duration of response)
Benboubker L, et al.	Lenalidomide + low dose dexamethasone (continuous)	75%	25.5 months

ORR overall response rate, PFS progression free survival

*For full bibliographic citations see last slide

Preferred Induction Regimens for Newly Diagnosed MM: Patients ineligible for transplant

Study*	Treatment	ORR	PFS
Niesvizky, et al.	Bortezomib + dexamethasone	73%	No difference
Richardson P, et al.	Bortezomib + lenalidomide + dexamethasone	100%	75% at 18 months
Kumar S, et al.	Cyclophosphamide + bortezomib + dexamethasone	88%	42% at 5 years

ORR overall response rate, PFS progression free survival

*For full bibliographic citations see last slide

Patient Case

KH begins treatment with lenalidomide, bortezomib and dexamethasone, 28 day cycles. After her second cycle, you learn she is having difficulty with transportation. KH would like to know if there is an all oral regimen that she can transition to for treatment of her multiple myeloma.

Ixazomib: First and Only Oral Proteasome Inhibitor

- Early clinical studies demonstrated ixazomib well-tolerated and active in multiple myeloma
- Phase 1 study established weekly dosing for ixazomib
- Population pharmacokinetic analysis determined that a change from body surface area (BSA) based dosing to fixed dosing was feasible
- On November 15, 2015 ixazomib was FDA-approved based on the results of the TOURMALINE-MM1 trial.


Kumar SK, et al. Blood Cancer J. 2105;Aug 14;doi:10.1038/bcj.2015.60.

Kumar SK, et al. Lancet Oncol 2014;15:1503-12.

Gupta N, et al. Br J Clin Pharmacol. 2015;79:789-800.

Kumar SK, et al. Blood. 2014;124:1047-55.

TOURMALINE-MM1



ECOG eastern cooperative oncology group, OS overall survival, PFS progression free survival

Moreau P, et al. N Engl J Med. 2016;374:1621-34.

TOURMALINE-MM1

- Progression Free Survival (PFS) was significantly longer by 40% with ixazomib as triplet therapy
 - 20.6 versus 14.7 months for ixazomib and placebo, respectively
 - Hazard ratio for disease progression or death 0.74 (95% confidence interval 0.59-0.94; P=0.01)
- PFS benefit held consistently for all pre-specified patient subgroups: high risk cytogenetics, International staging system (ISS) stage III, >75 years of age, 2-3 prior therapies
- Overall response rates 78.3% and 71.5% in the ixazomib and placebo group, respectively (P = 0.04)
- Median overall survival not yet reached

TOURMALINE-MM1

- Median number of cycles were 17 and 15 in the ixazomib and placebo group, respectively (range for ixazomib 1-34 cycles)
- Thromboprophylaxis according to American Society of Clinical Oncologists or institutional standard was required
 - Venous thromboembolism (VTE) occurred in 8% versus 11% of ixazomib and placebo, respectively
- Gastrointestinal events and rash were more common with ixazomib occurring mostly during cycles 1-3 and low grade
- Peripheral neuropathy was 27% and 22% in the ixazomib and placebo groups, respectively

Is Ixazomib Use Safe in Severe Renal Impairment or End Stage Renal Disease (ESRD)?

- Pharmacokinetic evaluation of single dose ixazomib in patients with normal ($\text{crcl} \geq 90 \text{ml/min}$), impaired ($\text{crcl} < 30 \text{ml/min}$) or end stage renal disease requiring hemodialysis
- Evaluated after a single 3mg dose of ixazomib
- Highly protein bound (99%) in all groups
- Systemic exposures were higher with renal dysfunction (38% and 39% in impaired and ESRD, respectively)
- Grade 3 and 4 adverse events were more frequent in the renally impaired and ESRD groups versus the normal groups as were serious adverse events

Ixazomib Summary

- Ixazomib in combination with lenalidomide and dexamethasone represents the first all oral triplet regimen for multiple myeloma. It demonstrates efficacy and is well tolerated
- Ixazomib are gelatin capsules and should not be refrigerated but does need to be stored at temperatures that do not exceed 86 degrees Fahrenheit or are freezing
 - Manufacturer recommends to avoid shipping ixazomib on ice and to use corrugated cartons for specialty pharmacy shipping
- Ixazomib should be taken on an empty stomach
- Safety of use of ixazomib in patients with creatinine clearance <30ml/min remains unclear
- Currently supported in the relapsed and/or refractory setting and being evaluated for use in maintenance and front line setting

Question 7

KH achieved a very good partial response with ixazomib, lenalidomide and dexamethasone and went on to consolidation with autologous stem cell transplantation. KH declined maintenance therapy. Two years later her immunofixation tests detect M-protein and her FLC ratio increases to 5.01 mg/dL. Which of the following therapies would be appropriate for KH's relapsed disease?

- A
 carfilzomib, pomalidomide and dexamethasone
- B
 lenalidomide, dexamethasone
- C
 bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, etoposide (VDT-PACE)
- D
 elotuzumab, lenalidomide and dexamethasone

Question 7

Your poll will show here

1

Install the app from
pollev.com/app

2


Make sure you are in
Slide Show mode

Still not working? Get help at pollev.com/app/help

or

[Open poll in your web browser](#)

Elotuzumab Mechanism of Action



ELOQUENT-2

- Adults with multiple myeloma and measurable disease who had received 1-3 prior therapies

Treatment cohort (n=321)	Active control cohort (n=325)
<ul style="list-style-type: none">• Elotuzumab 10mg/kg IV on days 1,8,15,22 for cycles 1 and 2. For cycles 3 and beyond on days 1,15• Lenalidomide 25mg PO on days 1-21• Dexamethasone 40mg PO weekly (on the weeks without elotuzumab) and 8mg IV plus 28mg PO weekly with elotuzumab	<ul style="list-style-type: none">• Lenalidomide 25mg PO on days 1-21• Dexamethasone 40mg PO on days 1,8,15,22

ELOQUENT-2

- Co-primary endpoints were PFS and overall response rates (ORR)
 - Median PFS for elotuzumab was 19.4 months and 14.9 months for control arm. Hazard ratio for disease progression and death of 0.7 (95% CI, 0.57-0.85;P<0.001)
 - ORR were 79% for elotuzumab and 66% for control arm (odds ratio for the elotuzumab group versus the control group, 1.9;95% CI, 1.4-2.8;P<0.001)
- No notable differences in pain severity from baseline and quality of life (per EORTC QLQ-C30) between the two groups

ELOQUENT-2

- More patients experienced grade 3-4 lymphocytopenia in the elotuzumab arm (77% versus 49%)
- Rate of herpes zoster infection was higher in the elotuzumab group when compared with control (incidence per 100 patient years, 4.1 versus 2.2)
- Infusion reactions (e.g. pyrexia, chills, hypertension) occurred in 33 patients with most occurring with the first dose and no grade 4 or 5 reaction

Elotuzumab Summary

- Elotuzumab is a well tolerated triplet regimen and demonstrates improved ORR and PFS when used in combination
 - Lacks single agent activity
- Patients should receive premedications for elotuzumab, herpes zoster prophylaxis and standard thromboprophylaxis
- Dexamethasone dosing is complicated and care should be taken with regard to patient adherence
- Key role for pharmacists is assistance with adherence and synchronization of oral therapies with parenteral cycles

Patient Case

KH tolerated elotuzumab, lenalidomide and dexamethasone. Unfortunately, her myeloma progressed after 8 cycles and her therapy was changed to carfilzomib, pomalidomide and dexamethasone. After four cycles of this therapy, she developed a soft tissue plasmacytoma in the right flank.

Question 8

Which of the following is the best therapeutic plan for KH?

- A** Continue current therapy (e.g. carfilzomib, pomalidomide, dexamethasone)
- B** Bortezomib, doxorubicin, thalidomide, cisplatin, dexamethasone, cyclophosphamide, etoposide (VDT-PACE)
- C** Daratumumab monotherapy
- D** Pomalidomide and dexamethasone

Question 8

Your poll will show here

1

Install the app from
pollev.com/app

2

Make sure you are in
Slide Show mode

Still not working? Get help at pollev.com/app/help
or

[Open poll in your web browser](#)

Daratumumab

- Humanized monoclonal antibody that targets CD38, a transmembrane protein highly expressed on malignant plasma cells
- Binding of daratumumab to CD38 triggers complement activation and complement dependent cytotoxicity
- Daratumumab also triggers antibody dependent cellular cytotoxicity (ADCC)
 - Modulation of enzymatic activation
 - Apoptosis after cross linking

DARA-GEN501

- Phase 1-2, open label, multicentered trial of dose-escalation and dose expansion
- Primary outcome was safety with secondary efficacy outcomes that included pharmacokinetics, objective response, relative reduction in M-protein/FLC, time to disease progression, duration of response, PFS and overall survival (OS)
- With higher doses of daratumumab, a new assay was used to measure disease response

DARA-GEN501

- Patients were adults, with ECOG ≤ 2 and measurable disease
- Part 1 dose escalation up to 24mg/kg, part 2 is dose expansion with cohorts receiving 8mg/kg and cohorts receiving 16mg/kg
- The primary endpoint was safety with secondary endpoints that included pharmacokinetic analysis, reduction in M-protein, light chains, duration of response, time to progression, PFS, OS

DARA-GEN501

- Safety events were mild, 71% of patients experienced grade 1 and 2 infusion reactions
- Adverse events were not dose related

Part 1: Dose-Escalation Study

- No maximum tolerated dose was identified
- 33% of patients had a partial response

Part 2: Dose-Expansion Study

Cohort	8 mg/kg	16 mg/kg
Reduction in M-Protein	15% of patients	46% of patients
Overall response rate	10%	36%
PFS	2.4 months	5.6 months
Median time to first response		0.9 months
Median duration of response	6.9 months	<ul style="list-style-type: none"> • Not reached • 65% of responders progression-free at 12 months

SIRIUS

- Phase 2, two part, open label, multicenter study
- ECOG ≤ 2
- Included adult patients with secretory myeloma and evidence of disease progression within 60 days of the last dose of the most recent regimen
 - Responded to one prior regimen
 - Received an alkylating agent
 - Received at least 3 prior regimens that included a proteasome inhibitor and immunomodulating drug
 - Double refractory disease to most recent proteasome inhibitor and immunomodulating drug

SIRIUS

- Phase 1 evaluated 8mg/kg and 16mg/kg doses. The 8mg/kg cohort did not meet criteria for expansion (dose likely did not meet trough threshold for saturation) but 16mg/kg went on to phase 2 dose expansion

	Daratumumab 16mg/kg (n=106)
ORR	31 (29.2%, 20.8-38.9)
Clinical benefit rate	36 (34%, 25-43.8)
≥ Very good partial response	13 (12.3%, 6.7-20.1)
Stable disease	46 (43.4%, 33.8-53.4)
Progressive disease	18 (17%, 10.4-25.5)

Daratumumab Improves OS

- Combined analysis of the DARA-GEN501 and SIRIUS trials demonstrates overall survival benefit with daratumumab monotherapy in heavily pretreated patients
- ORR 31%
- Median OS 19.9 months
 - Median OS has not been reached in responders

Daratumumab in Combination

- Pretreatment with immunomodulation has demonstrated enhanced antibody dependent cellular cytotoxicity in multiple myeloma cells through activation of natural killer cells.
 - Allows for synergistic activity to take place between the immunomodulatory drug and daratumumab
 - Immunomodulation to activate T and natural killer cells coupled with daratumumab-induced antibody dependent cellular cytotoxicity
- Synergistic activity may overcome drug resistance mechanisms of myeloma cells

Daratumumab in Combination

- Daratumumab + Pomalidomide + Dexamethasone

	ORR	VGPR
Daratumumab monotherapy	36%	13%
Daratumumab + pomalidomide + dexamethasone	71%	43%

Lokhorst, et al. N Engl J Med. 2015;373;1207-19.

Chari A, et al. Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma. Paper presented at: American Society of Hematology 2015; Orlando, FL

Daratumumab Summary

- Daratumumab represents a viable treatment option for patients with disease refractory to both proteasome inhibitors and immunomodulatory agents
- Daratumumab does interfere with blood typing and a type and screen should be obtained prior to therapy
- Cycle one day one infusions may require a lengthy infusion time
- Patients should receive prophylaxis for herpes zoster infection
 - Prophylaxis for infusion-related reactions
 - Premedication with montelukast?

Future Directions

- Daratumumab is currently being studied in combination with various multiple myeloma backbone regimens
- Specialty pipeline includes other oral proteasome inhibitors and histone deacetylase drugs

Supportive Care

- All patients receiving an immunomodulating agent in combination with corticosteroids should receive anticoagulation prophylaxis
 - Aspirin 81-325mg daily if no additional risk factors
 - If risk factors present enoxaparin 40mg SC daily
- Herpes zoster prophylaxis should be used in patients receiving elotuzumab and daratumumab
- Patients receiving daratumumab may consider a medic alert bracelet in case a blood transfusion is required during treatment

Conclusions

- Ixazomib allows for the first all oral triplet multiple myeloma regimen
- Elotuzumab does not demonstrate single agent activity but is effective in combination with lenalidomide and dexamethasone
- Daratumumab demonstrates single agent activity in heavily pretreated and dual refractory patients and early studies suggest an overall survival benefit

Full Reference Citations for Preferred Regimens in Newly Diagnosed MM

Transplant candidates

- Harousseau JL, et al. J Clin Oncol. 2010;28:4621-9.
- Sonneveld P, et al. J Clin Oncol. 2012;30:2946-55.
- Cavo M, et al. Lancet. 2010;376:2075-85.
- Rosinol L, et al. Blood. 2012;120:1589-96
- Zonder JA, et al. Blood. 2007;110:abstract 77.
- Gay F, et al. Blood 2010;115:1343-50.
- Richardson P, et al. Blood. 2010;116:679-86.
- Roussel M, et al. J Clin Oncol. 2014;32:2712-7.
- Kumar S, et al. Blood. 2012;119:4375-82.
- Reeder, et al. Leukemia. 2009;23:1337-41.

Non-transplant candidates

- Palumbo, et al. Lancet. 2006;367:825-31.
- Palumbo, et al. Blood. 2008;112:3107-14.
- Facon T, et al. Lancet. 2007;370:1209-18.
- Hulin C, et al. J Clin Oncol. 2009;27:3664-70.
- Palumbo A, et al. N Engl J Med. 2012;366:1759-69.
- San Miguel JF, et al. N Engl J Med. 2008;359:906-17.
- Benboubker L, et al. N Engl J Med. 2014;371:906-17.
- Niesvizky, et al. Blood. 2011;118:Abstract 478.
- Richardson P, et al. Blood. 2010;116:679-86.
- Kumar S, et al. Blood. 2012;119:4375-82.

Questions?